Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'

Novartis CEO Vas Narasimhan warned that U.S. drug pricing policy under President Trump creates a "very difficult situation" and said the full effects of MFN pricing should become clear within the next 18 months. He added that if European and Japanese governments do not improve rewards for innovation, novel medicines could face delayed launches and reduced patient access. The comments are negative for pharma pricing power and highlight regulatory pressure across the healthcare sector.

Analysis

The market is still treating U.S. drug-pricing pressure as a Washington headline risk, but the bigger risk is strategic re-rating: if net price realization compresses in the U.S., global pharma will try to offset it by extracting more value ex-U.S., which is exactly where reimbursement systems are least flexible. That shifts bargaining power toward governments and payers in Europe and Japan, but the adjustment path is slow, so the near-term winner is not necessarily patients or payers — it is the biosimilar/generic ecosystem that can underwrite cheaper access while innovators delay launches or narrow indications.

For NVS specifically, this is less about an immediate earnings cut and more about pipeline optionality. A delayed international launch cadence can flatten the present value of late-stage assets by pushing revenue back 12-24 months, which matters more for high-growth oncology and specialty launches than for mature franchises. The second-order effect is that smaller biotech partners and CDMOs tied to launch sequencing could see a lumpier order profile, while large-cap peers with deeper U.S. exposure and better scale may absorb the policy shock more effectively.

Catalyst timing is important: the next 3-6 months are mostly sentiment and multiple compression, but the real data points arrive over the next 12-18 months as pricing negotiations, launch timing, and payer responses become visible in guidance. The setup turns more constructive only if European/Japanese policymakers signal meaningful reimbursement reform or if U.S. MFN implementation gets diluted in court or through administrative delay. Absent that, the path of least resistance is lower forward multiples for innovator pharma, especially where long-duration pipeline value is a bigger share of valuation.

Consensus may be underestimating how asymmetric the response can be: pharma companies can defend margins by prioritizing launches in markets with better economics, but that strategy trades near-term revenue for long-term patient access and political goodwill. That creates a hidden reputational cost and could feed a broader policy backlash, making this a multi-year negotiation rather than a one-off headline. The move may be underdone in names with the highest U.S. revenue sensitivity and least pricing flexibility, but overstated for diversified global innovators with strong cash generation and visible buybacks.

Key Decisions for Investors

• Short NVS on rallies over the next 1-2 weeks; use the recent policy warning as a catalyst for multiple compression rather than an earnings event. Risk/reward is favorable if the stock re-prices 5-8% lower on repeated policy headlines, with a tight stop if management updates guidance positively.
• Pair trade: long large-cap, U.S.-diversified pharma with stronger pricing power vs. short a basket of global innovators most exposed to ex-U.S. reimbursement pressure. Hold 3-6 months; this captures the relative winner from slower ex-U.S. launch economics without taking pure sector beta.
• Buy downside protection in NVS via 3-6 month puts or put spreads into policy-driven volatility. The cleanest expression is to own limited-premium downside on any relief rally, since the catalyst is slow-burn and consensus tends to fade regulatory headlines too quickly.
• Watch European and Japanese healthcare/payer names for a potential relative-value long if governments move to preserve access through reimbursement reform. This is a 6-18 month theme; the trade works only if political response accelerates and innovator margin pressure becomes visible in guidance.
• If you want to stay long pharma beta, rotate toward names with lower U.S. policy sensitivity and higher free-cash-flow visibility; avoid paying up for pipeline duration until there is evidence the pricing regime stabilizes.